Reach the investors backing rounds like this
Backed by Bain Capital Life Sciences, Forbion +6 more · verified emails and LinkedIn on Datapile
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder - MedCity News
OMass Therapeutics, an Oxford-based company, has raised $310 million in a Series C financing round. The funds will be used to advance its small-molecule pipeline for rare endocrine and immunology disorders, including a potential treatment for congenital adrenal hyperplasia. This financing is the second-largest private biotech round in Europe for 2026.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder MedCity News
You just read who funded OMass Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.